EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Retrospective Review of Multitarget Stool DNA as a Screening Test for Colorectal Cancer

Thomas K Kleinschmidt, Austin Clements, Mark A Parker, Steven D Scarcliff

The American Surgeon™ · 2023-04 · 89 (4) · 603-606

DOI: 10.1177/00031348211031844 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The American Surgeon™, online erschienen am 18.07.2021. Verfasst von Thomas K Kleinschmidt und 3 weiteren Autor:innen. Beteiligte Einrichtung: Brookwood Baptist Health Systems, Birmingham, AL, USA. Hauptthemen laut MEDLINE: Adenoma, Colonic Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To review the effectiveness of noninvasive multitarget stool DNA testing as a screening test for colorectal cancer.

Methods

We performed a retrospective review of patients referred to 2 high volume outpatient procedural centers for colonoscopy for positive Cologuard test. Positive findings for colorectal cancer based on pathologic findings and also advanced adenomas were recorded. Positive predictive value (PPV) was assessed.

Results

Of the 1585 patients evaluated and referred for colonoscopy from January 1, 2018 to November 1, 2019, for ICD-10 codes R19.5 (other fecal abnormalities) and K92.1 (melena), 84 were referred for a positive Cologuard test. Out of the 84, 6 were excluded based on family history of colon cancer in first degree relative or personal history of inflammatory bowel disease. Of the remaining 78 patients, 1 patient (1.3%) had colorectal cancer and 5 (6.4%) had advanced adenomas (>1 cm size, high grade dysplasia or villous). Postive predictive value for colorectal cancer was 1.3% and for precancerous lesions plus colorectal cancer was 7.7%. A total of 53 (68.0%) patients had either totally normal colonoscopy or hyperplastic polyps. Out of the 78 individuals in our study, 70 (89.7%) had normal findings, hyperplastic polyps, or non-advanced adenomas.

Conclusions

Multitarget stool DNA testing carries an unacceptably low PPV to be utilized as a screening test for colorectal cancer. The study fails to detect both adenomas and colon cancer at a higher rate than screening colonoscopy in selected studies. The advantage of being noninvasive has been noted to increase colorectal cancer screening in otherwise non-compliant Medicare patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenomaColonic NeoplasmsColorectal NeoplasmsAgedHumansColonoscopyDNAEarly Detection of CancerFecesMass ScreeningMedicareRetrospective StudiesUnited States

Stichwörter der Autor:innen

cologuardcolonoscopycolorectal cancermultitarget DNA stoolscreening

Substanzen

DNA

Autor:innen und Institutionen

  • Brookwood Baptist Health Systems, Birmingham, AL, USA.
  • St Vincent's Hospital, Birmingham, AL, USA.
  • Grandview Medical Center, Birmingham, AL, USA.
  • Edward Via College of Osteopathic Medicine, Auburn, AL, USA.

Zitieren

APA

Kleinschmidt, T. K., Clements, A., Parker, M. A., & Scarcliff, S. D. (2023). Retrospective Review of Multitarget Stool DNA as a Screening Test for Colorectal Cancer. The American Surgeon™, 89(4), 603-606. https://doi.org/10.1177/00031348211031844

Vancouver

Kleinschmidt TK, Clements A, Parker MA, Scarcliff SD. Retrospective Review of Multitarget Stool DNA as a Screening Test for Colorectal Cancer. The American Surgeon™. 2023;89(4):603-606. doi:10.1177/00031348211031844

BibTeX
@article{Kleinschmidt2023,
  author = {Kleinschmidt, Thomas K and Clements, Austin and Parker, Mark A and Scarcliff, Steven D},
  title = {Retrospective Review of Multitarget Stool DNA as a Screening Test for Colorectal Cancer},
  journal = {The American Surgeon™},
  year = {2023},
  volume = {89},
  number = {4},
  pages = {603--606},
  doi = {10.1177/00031348211031844}
}
Kostenlos starten →